Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Issue 49 (22nd November 2022)

• Record Type: Journal Article
• Authors: Hoshi, Shu-ling; Shono, Aiko; Seposo, Xerxes; Okubo, Reiko; Kondo, Masahide
• Is Part Of: Vaccine. Volume 40:Issue 49(2022)
• Page Start: 7057
• Page End: 7064
• Publication Date: 2022-11-22
• Subjects: Cost-effectiveness -- 23-valent pneumococcal polysaccharide vaccine -- Pneumococcal conjugate vaccine -- Economic evaluation -- Quality-adjusted life year -- Vaccination; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.10.010
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Cost-effectiveness analysis was performed for PCV15/PCV20 vaccination programmes. Replacing PPSV23 programme with PCV20 resulted in cost-savings. Replacing PPSV23 programme with PCV15 cost US$318 to gain one additional QALY. PCV20 vaccination programme was observed to be more favourable than PCV15. Abstract: Background: Despite the 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination programme implementation, pneumococcal disease (PD) remains an important cause of morbidity and mortality among the elderly in Japan, particularly since childhood pneumococcal conjugate vaccine (PCV) vaccination programme continues to alter the serotype PD distribution among the elderly. Recently, in the United States, PCV15/PCV20 were recommended for adults aged ≥ 65 years and those aged 19–64 years with certain underlying conditions. In Japan, PCV15 is under the approval application process and PCV20 undergoing clinical trials, which has warranted the need in evaluating their value for money. Methods: We conducted cost-effectiveness analyses with Markov model and calculated incremental cost-effectiveness ratios of PCV15/PCV20 vaccination programme compared to status quo from payers' perspective. Transition probabilities and utility weights in estimating quality-adjusted life-year (QALY), and disease treatment costs were either estimated or obtained from literature. To reflect the situation of COVID-19 pandemic, epidemiological data from 2020 and beyond were used. Results: Compared to the current vaccination programme, PCV20 vaccination programme gained more QALYs with less cost, while PCV15 vaccination programme cost ¥35, 020 (US$318, US$1 = ¥110) to gain an additional QALY. Replacing PPSV23 vaccination programme with PCV20 vaccination programme is cost-saving. One-way sensitivity analyses revealed that lower VE limits of PCVs against non-bacteremic pneumonia (NBP) have large impact to change the result from PCV20 vaccination programme dominated PPSV23 vaccination programme to PPSV23 vaccination programme dominated PCV20 vaccination programme. Conclusion: In the COVID-19 era, replacing current PPSV23 with a single-dose PCV15- or PCV20 immunisation programme for 65-year-old adults in Japan is highly cost-effective, while the PCV 20 vaccination programme was observed to be more favourable.